Featured Content
Interesting Myeloma Articles September 2021
Here are some interesting Myeloma journal articles and some of the most discussed on Twitter for September 2021. Black multiple myeloma patients undergoing upfront autologous stem cell transplant have similar survival outcomes compared to whites: a propensity-score...
Expert Recommendations & Patient Perspectives for Treating Relapsed/Refractory Multiple Myeloma
In this webcast, expert faculty discuss best practices in treating patients with relapsed/refractory multiple myeloma and discuss the patient's perspective on treatment options. Learners will also get a look ahead at emerging therapeutic strategies and clinical trials...
Overview of Key Early-phase CAR T-cell Therapy Studies in Relapsed or Refractory Multiple Myeloma
In this article, we look at some of the early-phase clinical trials, where chimeric antigen receptor (CAR) T-cell therapy has been targeted to the B-cell maturation antigen (BCMA) in patients with relapsed or refractory MM (RRMM). The anti-BCMA CAR T-cell...
What Are Chimeric Antigen Receptor (CAR) T-cells and What is Their Potential Target Site in Multiple Myeloma?
CAR T-cell structure CARs are typically composed of four regions: (1) an extracellular antigen-binding domain; (2) a hinge or spacer peptide; (3) a transmembrane domain that anchors the CAR to the cell membrane; and (4) one or more intracellular signalling domains...
Myeloma News
FDA Approves 8th Darzalex Faspro Indication for Myeloma Patients
Source: Myeloma Research News The U.S. Food and Drug Administration (FDA) has approved Darzalex Faspro (daratumumab and hyaluronidase), in combination with Kyprolis (carfilzomib) and the corticosteroid dexamethasone, for the treatment of adults with multiple myeloma...
FDA Approves 8th Darzalex Faspro Indication for Myeloma Patients
Source: Myeloma Research News The U.S. Food and Drug Administration (FDA) has approved Darzalex Faspro (daratumumab and hyaluronidase), in combination with Kyprolis (carfilzomib) and the corticosteroid dexamethasone, for the treatment of adults with multiple myeloma...
FDA Approves 8th Darzalex Faspro Indication for Myeloma Patients
Source: Myeloma Research News The U.S. Food and Drug Administration (FDA) has approved Darzalex Faspro (daratumumab and hyaluronidase), in combination with Kyprolis (carfilzomib) and the corticosteroid dexamethasone, for the treatment of adults with multiple myeloma...
FDA Approves 8th Darzalex Faspro Indication for Myeloma Patients
Source: Myeloma Research News The U.S. Food and Drug Administration (FDA) has approved Darzalex Faspro (daratumumab and hyaluronidase), in combination with Kyprolis (carfilzomib) and the corticosteroid dexamethasone, for the treatment of adults with multiple myeloma...
FDA Approves 8th Darzalex Faspro Indication for Myeloma Patients
Source: Myeloma Research News The U.S. Food and Drug Administration (FDA) has approved Darzalex Faspro (daratumumab and hyaluronidase), in combination with Kyprolis (carfilzomib) and the corticosteroid dexamethasone, for the treatment of adults with multiple myeloma...
FDA Approves 8th Darzalex Faspro Indication for Myeloma Patients
Source: Myeloma Research News The U.S. Food and Drug Administration (FDA) has approved Darzalex Faspro (daratumumab and hyaluronidase), in combination with Kyprolis (carfilzomib) and the corticosteroid dexamethasone, for the treatment of adults with multiple myeloma...
FDA Approves 8th Darzalex Faspro Indication for Myeloma Patients
Source: Myeloma Research News The U.S. Food and Drug Administration (FDA) has approved Darzalex Faspro (daratumumab and hyaluronidase), in combination with Kyprolis (carfilzomib) and the corticosteroid dexamethasone, for the treatment of adults with multiple myeloma...
FDA Approves 8th Darzalex Faspro Indication for Myeloma Patients
Source: Myeloma Research News The U.S. Food and Drug Administration (FDA) has approved Darzalex Faspro (daratumumab and hyaluronidase), in combination with Kyprolis (carfilzomib) and the corticosteroid dexamethasone, for the treatment of adults with multiple myeloma...
FDA Approves 8th Darzalex Faspro Indication for Myeloma Patients
Source: Myeloma Research News The U.S. Food and Drug Administration (FDA) has approved Darzalex Faspro (daratumumab and hyaluronidase), in combination with Kyprolis (carfilzomib) and the corticosteroid dexamethasone, for the treatment of adults with multiple myeloma...
FDA Approves 8th Darzalex Faspro Indication for Myeloma Patients
Source: Myeloma Research News The U.S. Food and Drug Administration (FDA) has approved Darzalex Faspro (daratumumab and hyaluronidase), in combination with Kyprolis (carfilzomib) and the corticosteroid dexamethasone, for the treatment of adults with multiple myeloma...
Recent Publications
Bullous Amyloidosis Masquerading as Pseudoporphyria
Cutis. 2021 Sep;108(3):E25-E28. doi: 10.12788/cutis.0370. ABSTRACT Amyloidosis is not a singular disease but describes a group of diseases that result from abnormalities in protein folding and metabolism, leading to β-sheet polymers and amyloid fibrils. Cutaneous...
Belantamab mafodotin for the treatment of multiple myeloma
Drugs Today (Barc). 2021 Nov;57(11):653-663. doi: 10.1358/dot.2021.57.11.3319146. ABSTRACT Multiple myeloma is the second most common hematologic malignancy worldwide. Despite the growing number of available therapeutic options and advances in the treatment since the...
Isatuximab for the treatment of multiple myeloma
Drugs Today (Barc). 2021 Nov;57(11):665-675. doi: 10.1358/dot.2021.57.11.3343690. ABSTRACT Isatuximab is an IgG1 monoclonal antibody targeting CD38 that has received regulatory approval in combination regimens for patients with relapsed/refractory multiple myeloma....
Analysis of the clinical effects and outcome of patients with double-hit high-risk multiple myeloma
Zhonghua Zhong Liu Za Zhi. 2021 Nov 23;43(11):1209-1214. doi: 10.3760/cma.j.cn112152-20200109-00016. ABSTRACT Objective: To compare the clinical features, clinical efficacy, and prognosis of patients with double-hit and non-double-hit high-risk multiple myeloma (MM)...
Extramedullary relapse in a patient with multiple myeloma: a rare cause of gastrointestinal perforation and massive bleeding
BMJ Case Rep. 2021 Nov 18;14(11):e243663. doi: 10.1136/bcr-2021-243663. ABSTRACT Multiple myeloma (MM) patients live longer due to more effective treatment, and we now see previously uncommon manifestations of MM, like extramedullary disease. We present a case of a...
Application of Hydrashift 2/4 daratumumab assay in eliminating interference of daratumumab on serum immunofixation electrophoresis
Zhonghua Xue Ye Xue Za Zhi. 2021 Oct 14;42(10):840-845. doi: 10.3760/cma.j.issn.0253-2727.2021.10.008. ABSTRACT Objective: To investigate the interference of daratumumab on immunofixation electrophoresis after treating plasma cell diseases and methods to eliminate the...
Central nervous system involvement in Multiple Myeloma-Diagnosis, treatment and outcome: A case report
J Pak Med Assoc. 2021 Nov;71(11):2659-2661. doi: 10.47391/JPMA.01825. ABSTRACT Multiple Myeloma is a clonal proliferation of plasma cells with bone marrow as the primary site of occurrence. Extramedullary multiple myeloma is uncommonly seen either at presentation or...
Aggressive Plasmablastic Myeloma With Extramedullary Cord Compression and Hyperammonemic Encephalopathy: Case Report and Literature Review
Anticancer Res. 2021 Nov;41(11):5839-5845. doi: 10.21873/anticanres.15403. ABSTRACT BACKGROUND: Plasmablastic myeloma is an aggressive subtype of multiple myeloma with overall poor prognosis. Spinal cord compression and hyperammonemic encephalopathy are two grave...
